Logo 400x400.jpg
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
December 28, 2023 07:00 ET | CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
Logo 400x400.jpg
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
December 13, 2023 09:15 ET | CytoSorbents
CytoSorbents Strengthens Balance Sheet with $10.3M Registered Direct Offering. Insiders invest $435,000
Logo 400x400.jpg
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
November 09, 2023 16:15 ET | CytoSorbents
PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Logo 400x400.jpg
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
October 27, 2023 07:00 ET | CytoSorbents
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
Logo 400x400.jpg
CytoSorbents to Present at the 8th Annual Dawson James Conference
October 05, 2023 07:00 ET | CytoSorbents
CytoSorbents to Highlight Company Progress at Dawson James Small Cap Investor Growth Conference
Logo 400x400.jpg
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
September 27, 2023 07:00 ET | CytoSorbents
CytoSorbents summarizes real-world data from STAR Registry analysis being presented next week at European Association of Cardio-Thoracic Surgery Congress
Logo 400x400.jpg
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
September 19, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
Logo 400x400.jpg
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
September 11, 2023 11:32 ET | CytoSorbents
PRINCETON, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
Logo 400x400.jpg
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
September 01, 2023 16:43 ET | CytoSorbents
PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
Logo 400x400.jpg
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
August 31, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...